0000000000658454
AUTHOR
Eloise Thomas
showing 5 related works from this author
AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.
2019
International audience; AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been obser…
Functionalization of theranostic AGuIX® nanoparticles for PET/MRI/optical imaging
2019
International audience; A novel trifunctional imaging probe containing a chelator of radiometal for PET, a NIR heptamethine cyanine dye, and a bioconjugatable handle, has been grafted onto AGuIX® nanoparticles via a Michael addition reaction. The resulting functionalized nanoparticles have been fully characterized, radiolabelled with 64Cu, and evaluated in a mice TSA tumor model using multimodal (PET/MRI/optical) imaging.
Functionalization of ultrasmall nanoparticles for theranosctic applications
2015
International audience
AGuIX modifications for active tumor targeting and radiolabelling
2014
International audience
Radiolabeling for long term biodistribution of ultrasmall nanoparticles designed for radiotherapy guided by MRI
2016
International audience